A discovery that thiazide diuretics work partly through the endocannabinoid system reveals that physicians have been modulating this system in hypertension patients for over sixty years without knowing it.
Cardiovascular researchers, pharmacologists, and anyone interested in how the endocannabinoid system intersects with mainstream medicine.
What the researchers found
The phospholipase NAPE-PLD was identified as a systemic target of thiazide diuretics, meaning these common blood pressure medications produce their chronic therapeutic effects partly by generating anandamide and other protective lipid signaling molecules through the endocannabinoid system.
Why it matters
This reframes our understanding of one of the most widely prescribed classes of blood pressure medication. Knowing that thiazides work partly through the endocannabinoid system opens the door to designing more targeted cardiovascular therapies.
The numbers in context
Over sixty years of clinical thiazide use. CB1 agonists caused hypotension but risked tachycardia, heart, and kidney damage. FAAH inhibitors normalized blood pressure in hypertensive rats.
How the study worked
State-of-the-art narrative review synthesizing thirty years of research on endocannabinoid system modulation for hypertension, including the author's discovery of NAPE-PLD as a thiazide target.
What this study cannot tell us
As a narrative review, this reflects a selective synthesis rather than a systematic evaluation of all evidence. The NAPE-PLD mechanism is relatively new and requires further validation.
How to read the evidence
Well-supported mechanistic discovery backed by decades of clinical thiazide use, though the specific NAPE-PLD pathway requires further clinical validation.
When this study was published
2025 publication.
The bigger picture
Previous attempts to directly target the endocannabinoid system for cardiovascular disease were derailed by side effects. The thiazide-NAPE-PLD discovery suggests a subtler, clinically validated approach to ECS modulation has been hiding in plain sight.
Questions still open
- Could new drugs targeting the NAPE-PLD thiazide-binding site offer better cardiovascular protection with fewer side effects?
- Do individual differences in endocannabinoid system function explain why some patients respond better to thiazides?
Common questions
What is NAPE-PLD?
Why did earlier attempts to target the endocannabinoid system for blood pressure fail?
Read the original research
State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.
American journal of hypertension
Citation
Garau, Gianpiero. (2025). State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.. American journal of hypertension. https://doi.org/10.1093/ajh/hpaf174
Explore the wider topic
- Cannabis and Your Cardiovascular System: Heart Risk, Stroke, and What the Research Shows
- Cannabis and Your Heart: What the Cardiovascular Research Shows
- Coughing Up Black Stuff After Quitting Weed: What It Means
- Lung Recovery After Quitting Weed: The Complete Timeline
- Weed and Your Lungs: Recovery Timeline After Quitting
- Quitting Weed as a Woman: Hormones, Cycles, and Recovery
- Cannabis, Weight, and Diet: What Quitting Does to Your Appetite
- Sex After Quitting Weed: What Changes and What Doesn't
- Cannabis and Driving: DUI Laws, Impairment Science, and What You Need to Know
- Weed and Acne: Can Quitting Cannabis Clear Your Skin?
- Weed and Fertility: What Couples Should Know
- Weed and Your Gut: How Cannabis Affects Digestion
- Weed and Your Heart: Cardiovascular Effects and Recovery
- Weed, Testosterone, and Male Health: What the Research Actually Shows